PL1806359T3 - Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II - Google Patents

Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II

Info

Publication number: PL1806359T3
Authority: PL; Poland
Prior art keywords: molecules; tumour; present; relates; hla
Prior art date: 2005-09-05

Application number

PL07007915T

Other languages

English (en)

Inventor

Jörn Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2005-09-05

Publication date

2010-08-31

2005-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2010-08-31 Publication of PL1806359T3 publication Critical patent/PL1806359T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL07007915T 2005-09-05 2005-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II PL1806359T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (en)	2005-09-05	2005-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP07007915A EP1806359B1 (en)	2005-09-05	2005-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number	Publication Date
PL1806359T3 true PL1806359T3 (pl)	2010-08-31

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PL05019254T PL1760088T3 (pl)	2005-09-05	2005-09-05	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL07007914T PL1806358T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL07007915T PL1806359T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL09011319T PL2135878T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami HLA klasy II
PL06791838T PL1922335T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL05019254T PL1760088T3 (pl)	2005-09-05	2005-09-05	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL07007914T PL1806358T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL09011319T PL2135878T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami HLA klasy II
PL06791838T PL1922335T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II

Country Status (23)

Country	Link
US (6)	US10196432B2 (pl)
EP (6)	EP1760088B1 (pl)
JP (1)	JP5627180B2 (pl)
KR (3)	KR101386827B1 (pl)
CN (3)	CN105440119A (pl)
AT (5)	ATE388164T1 (pl)
AU (2)	AU2006289290B2 (pl)
BR (1)	BRPI0615462A2 (pl)
CA (2)	CA2621389C (pl)
CY (5)	CY1107973T1 (pl)
DE (4)	DE602005005196T2 (pl)
DK (5)	DK1760088T3 (pl)
EA (1)	EA013876B1 (pl)
ES (5)	ES2341802T3 (pl)
HK (1)	HK1220709A1 (pl)
HR (2)	HRP20100128T1 (pl)
NO (1)	NO340870B1 (pl)
NZ (2)	NZ588813A (pl)
PL (5)	PL1760088T3 (pl)
PT (5)	PT1806359E (pl)
SI (5)	SI1760088T1 (pl)
UA (1)	UA98295C2 (pl)
WO (1)	WO2007028574A2 (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1760088T3 (pl) *	2005-09-05	2008-10-31	Immatics Biotechnologies Gmbh	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
BRPI0813621A2 (pt)	2007-07-27	2017-05-09	Immatics Biotechnologies Gmbh	imunoterapia contra tumores neuronais e cerebrais
CN105566450A (zh)	2007-07-27	2016-05-11	伊玛提克斯生物技术有限公司	免疫疗法的新型免疫抗原表位
WO2009015841A1 (en)	2007-07-27	2009-02-05	Immatics Biotechnologies Gmbh	Composition of tumour-associated peptides and related anti-cancer vaccine
CA2696591C (en) *	2007-08-20	2016-10-11	Oncotherapy Science, Inc.	Cdh3 peptide and medicinal agent comprising the same
CA2991175A1 (en) *	2007-11-01	2009-05-07	Mayo Foundation For Medical Education And Research	Hla-dr binding peptides and their uses
DK2105501T3 (da)	2008-03-27	2015-11-23	Immatics Biotechnologies Gmbh	Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer
SI2113253T1 (sl) *	2008-04-30	2010-06-30	Immatics Biotechnologies Gmbh	Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PT2119726E (pt)	2008-05-14	2015-03-30	Immatics Biotechnologies Gmbh	Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
DK2172211T3 (en) *	2008-10-01	2015-02-16	Immatics Biotechnologies Gmbh	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
DK2623517T3 (en) *	2009-01-28	2015-11-23	Ind Tech Res Inst	Urine and serum biomarkers associated with diabetic nephropathy
WO2011073215A2 (en)	2009-12-14	2011-06-23	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CA2821582A1 (en)	2010-12-14	2012-06-21	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
KR101976882B1 (ko) *	2011-03-23	2019-05-09	프레드 헛친슨 켄서 리서치 센터	세포 면역요법용 방법 및 조성물
TWI819228B (zh) *	2013-08-05	2023-10-21	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
HRP20192262T1 (hr)	2013-08-05	2020-03-06	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr)	2014-05-09	2019-12-13	Immatics Biotechnologies Gmbh	Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
HRP20211754T1 (hr)	2014-12-23	2022-03-04	Immatics Biotechnologies Gmbh	Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PT3388075T (pt)	2015-03-27	2023-08-18	Immatics Biotechnologies Gmbh	Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
CA2989483A1 (en) *	2015-06-19	2016-12-22	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
MA42294B1 (fr)	2015-07-01	2020-11-30	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN107912043B (zh)	2015-07-06	2022-02-18	伊玛提克斯生物技术有限公司	用于食管癌和其他癌症免疫治疗的新型肽和肽组合物
GB201512369D0 (en)	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CN109734777B (zh)	2015-08-28	2023-04-07	伊玛提克斯生物技术有限公司	用于各种癌症免疫治疗的新型肽、肽组合物和支架
MY198087A (en)	2015-10-05	2023-07-31	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY196837A (en)	2015-12-11	2023-05-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
CN108601731A (zh)	2015-12-16	2018-09-28	磨石肿瘤生物技术公司	新抗原的鉴别、制造及使用
GB201522667D0 (en)	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA54832A (fr)	2016-03-01	2021-12-01	Immatics Biotechnologies Gmbh	Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
RS67172B1 (sr) *	2016-03-31	2025-09-30	Biontech Us Inc	Neoantigeni i postupci za njihovu upotrebu
PE20181896A1 (es)	2016-04-06	2018-12-11	Immatics Biotechnologies Gmbh	Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide agua (lma) y otros tipos de cancer
CR20200608A (es)	2016-04-21	2021-01-20	Immatics Biotechnologies Gmbh	INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
SG11201808629UA (en)	2016-04-21	2018-11-29	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
EP4099015A1 (en)	2016-06-10	2022-12-07	Gadeta B.V.	Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
TWI796299B (zh)	2016-08-26	2023-03-21	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
WO2018138257A1 (en)	2017-01-27	2018-08-02	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EA201991444A1 (ru)	2017-01-27	2019-12-30	Имматикс Байотекнолоджиз Гмбх	Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
SI3573647T1 (sl)	2017-01-27	2023-07-31	Immatics Biotechnologies Gmbh	Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
EP3576767A4 (en) *	2017-02-06	2020-12-02	Academia Sinica	RECOMBINATED PROTEINS AND THEIR USES
CN111533796A (zh)	2017-04-10	2020-08-14	伊玛提克斯生物技术有限公司	用于癌症免疫治疗的肽及其肽组合物
TW201841934A (zh)	2017-04-10	2018-12-01	德商英麥提克生物技術股份有限公司	用於治療癌症免疫治療的新穎肽及其肽組合物
CN111533799A (zh)	2017-04-10	2020-08-14	伊玛提克斯生物技术有限公司	用于白血病和其他癌症免疫治疗的肽和肽组合物
EA201992416A1 (ru)	2017-04-10	2020-02-25	Имматикс Байотекнолоджиз Гмбх	Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
CN119080881A (zh)	2017-07-07	2024-12-06	伊玛提克斯生物技术有限公司	用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
US10800823B2 (en)	2017-07-07	2020-10-13	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US11051539B2 (en)	2017-09-18	2021-07-06	S & P Ingredient Development, Llc	Low sodium salt substitute with potassium chloride
EP4576103A3 (en)	2017-10-10	2025-08-27	Gritstone bio, Inc.	Neoantigen identification using hotspots
EP3714275A4 (en)	2017-11-22	2021-10-27	Gritstone bio, Inc.	REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
JP7470640B2 (ja)	2018-02-09	2024-04-18	イマティクスユーエス，アイエヌシー．	Ｔ細胞を製造する方法
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
JP7480064B2 (ja) *	2018-02-27	2024-05-09	グリットストーンバイオインコーポレイテッド	パンアレルモデルによる新生抗原の特定方法
EP3539562A1 (en) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immunotherapeutic peptides
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en)	2018-09-17	2024-04-02	Immatics Biotechnologies Gmbh	B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
US20200384028A1 (en)	2019-06-06	2020-12-10	Immatics Biotechnologies Gmbh	Sorting with counter selection using sequence similar peptides
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
CA3146298A1 (en) *	2019-07-30	2021-02-04	University Health Network	T cell receptors and methods of use thereof
EP3827840A1 (en) *	2019-11-29	2021-06-02	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	Teipp peptide variant and uses thereof
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
CN120712104A (zh) *	2022-10-14	2025-09-26	广东天科雅生物医药科技有限公司	针对神经胶质瘤的肽疫苗及其用途
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (pl) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
IN151589B (pl)	1978-12-22	1983-05-28	Biogen Nv
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en) *	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
EP0636175A1 (en) *	1992-04-03	1995-02-01	La Jolla Cancer Research Foundation	Decorin fragments and methods of inhibiting cell regulatory factors
CA2142007C (en) *	1992-08-11	2007-10-30	Robert Glen Urban	Immunomodulatory peptides
EP0725799A1 (en) *	1993-10-29	1996-08-14	Dana-Farber Cancer Institute, Inc.	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
CA2195642A1 (en)	1994-07-27	1996-02-08	Andreas Suhrbier	Polyepitope vaccines
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
CA2243235C (en)	1996-01-17	2010-08-10	Imperial College Innovations Limited	Immunotherapy using cytotoxic t lymphocytes (ctl)
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
AU6241698A (en) *	1997-01-21	1998-08-07	Human Genome Sciences, Inc.	Tace-like and matrilysin-like polypeptides
US6316213B1 (en) *	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
ES2245048T3 (es) *	1997-10-15	2005-12-16	Pharis Biotec Gmbh	Factor de crecimiento derivado de cadherina y su uso.
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
GB2373500B (en) *	2000-02-04	2004-12-15	Aeomica Inc	Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2002008262A2 (en) *	2000-07-26	2002-01-31	Stanford University	Bstp-5 proteins and related reagents and methods of use thereof
WO2002050103A2 (en)	2000-12-20	2002-06-27	Glaxosmithkline Biologicals S.A.	Tumour-related antigens
WO2002078516A2 (en)	2001-03-30	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
US7705120B2 (en) *	2001-06-21	2010-04-27	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2005500059A (ja) *	2001-08-13	2005-01-06	ダナ−ファーバーキャンサーインスティテュートインク．	ペリオスチンに基づく診断アッセイ法
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
AU2002335824A1 (en) *	2001-10-12	2003-04-22	Case Western Reserve University	Neuronal regeneration
AU2003215244A1 (en) *	2002-02-14	2003-09-04	Curagen Corporation	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
AU2002368151A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
AU2003295328A1 (en) *	2002-10-02	2004-04-23	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2004110345A2 (en) *	2002-10-29	2004-12-23	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004106495A2 (en) *	2003-05-29	2004-12-09	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005014635A2 (en) *	2003-07-15	2005-02-17	Genova Ltd.	Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
PL1760088T3 (pl) *	2005-09-05	2008-10-31	Immatics Biotechnologies Gmbh	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL1760089T3 (pl) *	2005-09-05	2010-03-31	Immatics Biotechnologies Gmbh	Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
EP1795599A1 (en) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Methods for generating antigen-specific effector T cells

2005
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Expired - Lifetime
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Expired - Lifetime
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Expired - Lifetime
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
2006
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en not_active Ceased
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
2007
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
CN101287754B (zh)	2013-02-13
CY1110187T1 (el)	2015-01-14
EP2135878B1 (en)	2011-11-09
US20100040590A1 (en)	2010-02-18
DK1806358T3 (da)	2010-06-28
NZ566104A (en)	2011-04-29
EP1806358A3 (en)	2007-10-03
NZ588813A (en)	2011-06-30
SI2135878T1 (sl)	2012-03-30
DE602005005196T2 (de)	2008-06-26
EP1806358A2 (en)	2007-07-11
DE602006011030D1 (de)	2010-01-21
US7833970B2 (en)	2010-11-16
ATE388164T1 (de)	2008-03-15
ES2337399T3 (es)	2010-04-23
CY1107973T1 (el)	2013-09-04
ATE451388T1 (de)	2009-12-15
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
US10196432B2 (en)	2019-02-05
HRP20100128T1 (hr)	2010-04-30
HRP20110981T1 (hr)	2012-02-29
US20080207520A1 (en)	2008-08-28
SI1806359T1 (sl)	2010-06-30
HK1220709A1 (zh)	2017-05-12
EP1806359B1 (en)	2010-03-17
ES2302546T3 (es)	2008-07-16
ES2341295T3 (es)	2010-06-17
US20160115212A1 (en)	2016-04-28
ES2341802T3 (es)	2010-06-28
DK2135878T3 (da)	2012-02-27
CA2621389A1 (en)	2007-03-15
JP5627180B2 (ja)	2014-11-19
CA2929252A1 (en)	2007-03-15
CY1110051T1 (el)	2015-01-14
PT2135878E (pt)	2012-01-05
CY1109849T1 (el)	2014-09-10
KR20080052643A (ko)	2008-06-11
EP2135878A1 (en)	2009-12-23
PL1922335T3 (pl)	2010-05-31
DK1806359T3 (da)	2010-06-14
EP1922335B1 (en)	2009-12-09
PT1806359E (pt)	2010-05-25
KR20130019034A (ko)	2013-02-25
PT1806358E (pt)	2010-05-28
US20080206216A1 (en)	2008-08-28
US7833969B2 (en)	2010-11-16
DE602005005196D1 (de)	2008-04-17
AU2006289290A1 (en)	2007-03-15
SI1806358T1 (sl)	2010-06-30
JP2010502173A (ja)	2010-01-28
EP1806358B1 (en)	2010-03-17
CY1112186T1 (el)	2015-12-09
US20080206217A1 (en)	2008-08-28
PL2135878T3 (pl)	2012-06-29
ATE461215T1 (de)	2010-04-15
KR101386827B1 (ko)	2014-04-17
DE602005020047D1 (de)	2010-04-29
EA200800677A1 (ru)	2008-08-29
SI1922335T1 (sl)	2010-04-30
EP1760088B1 (en)	2008-03-05
ATE532795T1 (de)	2011-11-15
EP1760088A1 (en)	2007-03-07
NO340870B1 (no)	2017-07-03
US10618945B2 (en)	2020-04-14
CN103059104A (zh)	2013-04-24
US7807642B2 (en)	2010-10-05
UA98295C2 (ru)	2012-05-10
PL1806358T3 (pl)	2010-08-31
DE602005020046D1 (de)	2010-04-29
SI1760088T1 (sl)	2008-06-30
KR20130019033A (ko)	2013-02-25
EP2138509A1 (en)	2009-12-30
PL1760088T3 (pl)	2008-10-31
DK1760088T3 (da)	2008-06-09
CN103059104B (zh)	2015-10-28
HK1183678A1 (en)	2014-01-03
CN101287754A (zh)	2008-10-15
NO20081683L (no)	2008-04-04
DK1922335T3 (da)	2010-04-19
EP1806359A1 (en)	2007-07-11
EP1922335A2 (en)	2008-05-21
AU2006289290B2 (en)	2010-11-25
KR101386355B1 (ko)	2014-04-17
ATE461214T1 (de)	2010-04-15
PT1760088E (pt)	2008-05-14
AU2010236029A1 (en)	2010-11-18
AU2010236029B2 (en)	2012-06-28
PT1922335E (pt)	2010-03-03
CA2621389C (en)	2016-07-19
WO2007028574A9 (en)	2008-05-02
US20080206218A1 (en)	2008-08-28
WO2007028574A3 (en)	2007-05-24
EA013876B1 (ru)	2010-08-30
KR101386790B1 (ko)	2014-04-21
WO2007028574A2 (en)	2007-03-15
ES2373907T3 (es)	2012-02-10